Rivaroxaban in Peripheral Artery Disease after Revascularization
Marc P. Bonaca(University of Colorado Anschutz Medical Campus), William R. Hiatt(University of Colorado Anschutz Medical Campus)
Cited by 966
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k
Vorapaxar in the Secondary Prevention of Atherothrombotic Events
|New England Journal of Medicine|2012|941
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
|Circulation|2017|754
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
|New England Journal of Medicine|2016|628